Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11c(+)CD8(+) T cells in renal cell carcinoma

To improve the potential treatment strategies of incurable renal cell carcinoma (RCC), which is highly resistant to chemotherapy and radiotherapy, the present study established a combination therapy with immunostimulatory factor (ISTF) and anti-4-1BB monoclonal antibodies (mAbs) to augment the antit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ju, Seong-A, Park, Sang-Min, Joe, Yeonsoo, Chung, Hun Taeg, An, Won G., Kim, Byung-Sam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674882/
https://www.ncbi.nlm.nih.gov/pubmed/34976155
http://dx.doi.org/10.3892/ol.2021.13161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674882/
https://www.ncbi.nlm.nih.gov/pubmed/34976155
http://dx.doi.org/10.3892/ol.2021.13161

Ejemplares similares